Intervention of interest:

  • vedolizumab (Entyvio®, Takeda Pharmaceutical Co. Ltd.)

ICER published a Special Report on Entyvio® (vedolizumab, Takeda Pharmaceutical Co. Ltd.) for the treatment of ulcerative colitis and Crohn’s disease. This report will be submitted to the Centers for Medicare & Medicaid Services (CMS) as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.

Final Documents

Final Evidence ReportDownload
The ICER Snapshot: for PatientsDownload

ICER’s CEO and President, Sarah K. Emond, MPP stated:

“Over three million people in the United States suffer from inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. Our special report focuses on the medical evidence for and value of Entyvio, which is commonly used to treat both conditions. We recognize that our report will be one of many inputs CMS may consider, and we hope that it will support their ongoing efforts to build a reliable, value-based, transparent drug price negotiation process on behalf of the American people.”

For more information please contact [email protected].

ICER STAKEHOLDER OUTREACH LIST

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.

  • AbbVie Inc.
  • Accord BioPharma
  • Alvotech
  • Amgen Inc.
  • Biocon Biologics
  • Bio-Thera Solutions
  • Boehringer Ingelheim
  • Celltrion
  • Crohn’s and Colitis Foundation
  • Fresenius Kabi
  • Generation Patient
  • Girls with Guts
  • Janssen Pharmaceuticals
  • Meitheal Pharmaceuticals
  • Organon & Co.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sandoz Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Inc.

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.